arrow
K

Keertan Dheda

university of cape town
H指数:95
被引数:4.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Inflammatory biomarkers of asymptomatic and symptomatic tuberculosis

无症状和有症状结核病的炎症生物标志物

2026-07-250
OA
Reply to Adzemovic et al

回复Adzemovic et al.

2025-05-050
OA
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M™ adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial
2024-12-120
OAAI
Diagnostic Performance of Unstimulated IFN-γ (IRISA-TB) for Pleural Tuberculosis: A Prospective Study in South Africa and India

非刺激性ifn-γ (IRISA-TB) 对胸膜结核的诊断性能: 南非和印度的一项前瞻性研究

2024-09-240
OAAI
Recent advances in the treatment of tuberculosis

结核病治疗的最新进展

2024-09-0113
OA
Utility of Cerebrospinal Fluid Unstimulated Interferon-Gamma (IRISA-TB) as a Same-Day Test for Tuberculous Meningitis in a Tuberculosis-Endemic, Resource-Poor Setting

在结核病流行,资源贫乏的环境中,脑脊液非刺激性干扰素-γ (IRISA-TB) 作为结核性脑膜炎的当日测试的效用

2024-08-291
OAAI
Target regimen profiles for tuberculosis treatment

结核病治疗的目标方案概况

2024-08-011
OAAI
Review of Current Tuberculosis Human Infection Studies for Use in Accelerating Tuberculosis Vaccine Development: A Meeting Report

用于加速结核病疫苗研发的当前结核病人类感染研究综述:会议报告

2024-05-063
OAAI
SARS-CoV-2 Viral Replication Persists in the Human Lung for Several Weeks after Symptom Onset

症状发作后,SARS-CoV-2病毒复制在人肺中持续数周

2024-04-016
OAAI
Multidrug-resistant tuberculosis

耐多药结核病

2024-03-2427
OA
Frequency, kinetics and determinants of viable SARS-CoV-2 in bioaerosols from ambulatory COVID-19 patients infected with the Beta, Delta or Omicron variants
2024-03-056
OAAI